SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Swaak, A J.
Right arrow Articles by Smolen, J S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swaak, A J.
Right arrow Articles by Smolen, J S
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation

A JG Swaak

AJG Swaak, Department of Rheumatology, Medisch Centrum Rijnmond Zuid,Groene Hilledijlk 315, 3075 EA Rotterdam, The Netherlands

H G van den Brink

R JT Smeenk

Department of Auto-immune Diseases, Central Laboratory Blood Transfusion Service, Amsterdam, The Netherlands

K Manger

J R Kalden

Department of Internal Medicine III and Institute for Clinical Immunology, University Erlangen-Nurnberg, Erlangen, Germany

S Tosi

Rheumatology Unit, Istituto Ortopedico Gaetano Pini, Milano, Italy

Z Domljan

Department of Rheumatology and Rehabilitation, University Hospital Zagreb,Zagreb, Croatia

B Rozman

D Logar

Department of Rheumatology, Dr Peter Drzaj Hospital, Ljubljana, Slovenia

G Pokorny

L Kovacs

First Department of Internal Medicine, Dr A. Szent-Gyorgyi Medical University Centre, Szeged, Hungary

A Kovacs

Blood Transfusion Institute, Dr A. Szent-Gyorgyi Medical University Centre, Szeged, Hungary

P G Vlachoyiannopoulos

H M Moutsopoulos

Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece

H Chwalinska-Sadowska

Department of Connective Tissue Diseases, Institute of Rheumatology, Warsaw, Poland; 11Department of Internal Medicine, Medical University of Debrecen, Debrecen, Hungary

E Kiss

Department of Internal Medicine, Medical University of Debrecen, Debrecen, Hungary

N Cikes

B Anic

Division of ClinicalImmunology and Rheumatology, Department of Medicine, University Hospital Center, Zagreb

M Schneider

R Fischer

Medical Clinic, Department of Rheumatology, Heinrich-Heine University, Dusseldorf, Germany

S Bombardieri

M Mosca

Universita degli Studi di Pisa, Dipartimenti di Medicina Interna, Italy

W Graninger

J S Smolen

Department of Rheumatology, University of Vienna, Vienna, Austria

Data related to the disease course of patients with systemic lupus erythematosus (SLE) with special attention tothepersistence of disease activity in the long term are scarce. At this moment reliable figures are only knownabout the survival rate as a measure of outcome. The aim of this multicenter study was to describe the outcome ofSLE patients with a disease duration of greater than 10 y.Outcome parameters were two disease activity-scoring systems (SLEDAI and ECLAM), the end organ damage (SLICC/ACR damage index) and treatment. Our results are derived from 187SLE patients followed at 10 different centres in Europe over a period of 1 y. Serious clinical signs or exacerbations, defined by the occurrence or detoriation of already existing symptoms of renal and cerebral nervous systems were observed in 2 - 11% of the patients,seizures and psychosis in 3%, proteinuria in 11% and an increase in serum creatinine in 5% of the patients. No change took place in the overall damage index. Yet, the diseasecourse in most patients was characterized by periods of tiredness (42 - 60%), arthritis (20 - 25%), skin involvement such as malar rash (32 - 40%), migraine (15 - 20%), anaemia(15%) and leucopenia (17 - 19%). Summarizing these results it is shown that patients, still under care after such a long time of having this disease, do have a disease that is far from extinguished.

Key Words: SLE • disease activity • SLEDAI • ECLAM • damage index

Lupus, Vol. 10, No. 1, 51-58 (2001)
DOI: 10.1191/096120301666282314


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann Rheum DisHome page
R M Andrade, G S Alarcon, L A Gonzalez, M Fernandez, M Apte, L M Vila, G McGwin Jr, J D Reveille, and for the LUMINA Study Group
Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV)
Ann Rheum Dis, June 1, 2008; 67(6): 829 - 834.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
J. Nossent, N. Cikes, E. Kiss, A. Marchesoni, V. Nassonova, M. Mosca, M. Olesinska, G. Pokorny, B. Rozman, M. Schneider, et al.
Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual
Lupus, May 1, 2007; 16(5): 309 - 317.
[Abstract] [PDF]


Home page
LupusHome page
A Zink, R Fischer-Betz, K Thiele, J Listing, D Huscher, E Gromnica-Ihle, C Specker, M Schneider, and German Collaborative Arthritis Centres
Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the national database of the German Collaborative Arthritis Centres
Lupus, July 1, 2004; 13(7): 529 - 536.
[Abstract] [PDF]


Home page
BrainHome page
D. D. Mitsikostas, P. P. Sfikakis, and P. J. Goadsby
A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth
Brain, May 1, 2004; 127(5): 1200 - 1209.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
S Sundaramurthy, T M Bush, C M Neuwelt, and M M Ward
Time perspective predicts the progression of permanent organ damage in patients with systemic lupus erythematosus
Lupus, June 1, 2003; 12(6): 443 - 448.
[Abstract] [PDF]


Home page
Ann Rheum DisHome page
C Fiehn, Y Hajjar, K Mueller, R Waldherr, A D Ho, and K Andrassy
Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment
Ann Rheum Dis, May 1, 2003; 62(5): 435 - 439.
[Abstract] [Full Text] [PDF]



Advertisement